Avidity Biosciences (NASDAQ:RNA – Get Free Report) and NeuroSense Therapeutics (NASDAQ:NRSN – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.
Risk and Volatility
Avidity Biosciences has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Profitability
This table compares Avidity Biosciences and NeuroSense Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avidity Biosciences | -2,772.45% | -27.66% | -24.56% |
| NeuroSense Therapeutics | N/A | N/A | -286.31% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avidity Biosciences | $10.12 million | 355.08 | -$212.22 million | ($2.88) | -10.45 |
| NeuroSense Therapeutics | N/A | N/A | -$11.28 million | ($0.85) | -1.51 |
NeuroSense Therapeutics has lower revenue, but higher earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
1.0% of NeuroSense Therapeutics shares are held by institutional investors. 3.7% of Avidity Biosciences shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Avidity Biosciences and NeuroSense Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avidity Biosciences | 0 | 0 | 11 | 0 | 3.00 |
| NeuroSense Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
Avidity Biosciences currently has a consensus target price of $64.36, indicating a potential upside of 113.76%. Given Avidity Biosciences’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Avidity Biosciences is more favorable than NeuroSense Therapeutics.
Summary
NeuroSense Therapeutics beats Avidity Biosciences on 8 of the 13 factors compared between the two stocks.
About Avidity Biosciences
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
About NeuroSense Therapeutics
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson’s disease; and CogniC for the treatment of Alzheimer’s disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
